Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
- Approval paves the way for launch by Sanofi of the first Zealand invented product in the U.S.
- Triggers a $5 million milestone payment from Sanofi
- FDA is currently reviewing iGlarLixi, the fixed-ratio combination of AdlyxinTM (lixisenatide) and Lantus(r) (insulin glargine), with regulatory decision expected in August 2016
- Zealand is eligible to receive remaining milestone payments of up to $135 million as well as royalties on global sales
COPENHAGEN, Denmark, July 28, 2016 -- Zealand Pharma (Zealand), a biotechnology company, announces that the U.S. Food and Drug Administration (FDA) has granted approval of lixisenatide for the treatment of adults with type 2 diabetes. Lixisenatide, a once-daily prandial GLP-1 receptor agonist, was invented by Zealand and global development and commercial rights are licensed to Sanofi.
Lixisenatide has been approved in the U.S. under the brand name AdlyxinTMindicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, including in combination with oral anti-diabetes medication and/or basal insulin. There are an estimated 27.5 million adults with type 2 diabetes (American Diabetes Association, 2012) in the U.S., and the U.S market constitutes approximately 75% of the world market for GLP-1 receptor agonists (IMS, 2016).
Britt Meelby Jensen, President and Chief Executive Officer of Zealand commented: " Today is an important day for Zealand. With the FDA approval of AdlyxinTM we have successfully passed the final regulatory milestone for the first Zealand invented product to become available for diabetes patients in the significant U.S. market. We look forward to Sanofi's launch of AdlyxinTM, while awaiting the FDA's regulatory decision on iGlarLixi, the single product combination of AdlyxinTM and Lantus(r), expected in August 2016."
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: [email protected]
Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications
Tel: +45 50 60 36 89, email: [email protected]
